SILVER SPRING
Caplyta sNDA approved for schizophrenia relapse risk reduction
- Sponsor
- Johnson & Johnson $JNJ
- Drug
- Caplyta · lumateperone
- Indication
- schizophrenia
FDA approved a supplemental New Drug Application for Caplyta (lumateperone) based on long-term data supporting reduced relapse risk in schizophrenia.
What this means
Caplyta is an antipsychotic drug that helps regulate brain chemicals involved in schizophrenia symptoms. Today FDA approved Caplyta for reducing the risk of relapse in schizophrenia, based on long-term safety and effectiveness data. This decision gives patients and doctors a new option to help maintain stability and prevent symptom return in this chronic mental health condition.
Drug Watch — recent news on Caplyta
- Intra-Cellular Therapies highlights its psychiatry focus. The Nasdaq-listed biotech leans on Caplyta - ad-hoc-news.de
- Alternative to Meds Center Expands Educational Resources on Caplyta Side Effects and Holistic Recovery - EIN News
- What Just Happened to Intra-Cellular Therapies (ITCI) Stock - Kavout
- Caplyta Erectile Dysfunction: What Patients Need to Know - Ministerio de Salud Pública de Tucumán
- Lumatperone in Adjunctive MDD Treatment: Phase 3 Data and Meta-Analysis Findings - Psychiatric Times